Natural GLP-1 production, while essential for normal glucose homeostasis, is insufficient to treat established metabolic disease
Retatrutide is currently in Phase 3 clinical trials, with potential regulatory approval expected around 2026-2027 at the earliest, though timelines can change based on trial outcomes and regulatory review processes
Role of GLP-1 Receptor Agonists for Weight Loss Key studies including the SCALE and STEP trials are highlighted and the efficacy of the GLP-1 receptor agonists liraglutide and
This article examines the evidence for natural compounds that may influence GLP-1 and GIP activity, their safety considerations, and when to consult your GP about metabolic health concerns
Your muscles need the amino acids more than they need a larger dose
Traveling internationally can create even larger disruptions